Literature DB >> 15917568

Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas.

Ken B Waites1, Nipun B Reddy, Donna M Crabb, Lynn B Duffy.   

Abstract

Peptide deformylase inhibitor LBM-415 and seven other drugs were tested against Mycoplasma pneumoniae (100 isolates), Mycoplasma hominis (20 isolates), Mycoplasma fermentans (10 isolates), and Ureaplasma species (50 isolates). LBM-415 was active against M. pneumoniae (MICs, <or=0.008 microg/ml). It showed no activity against M. hominis and M. fermentans and modest activity against Ureaplasma spp.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15917568      PMCID： PMC1140545          DOI： 10.1128/AAC.49.6.2541-2542.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents.

Authors:  C Giglione; M Pierre; T Meinnel
Journal:  Mol Microbiol       Date:  2000-06       Impact factor: 3.501

2.  Resistance to anti-peptide deformylase drugs.

Authors:  Carmela Giglione; Thierry Meinnel
Journal:  Expert Opin Ther Targets       Date:  2001-06       Impact factor: 6.902

3.  Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Authors:  Kim Credito; Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

4.  The genome sequence of Mycoplasma hyopneumoniae strain 232, the agent of swine mycoplasmosis.

Authors:  F Chris Minion; Elliot J Lefkowitz; Melissa L Madsen; Barbara J Cleary; Steven M Swartzell; Gregory G Mahairas
Journal:  J Bacteriol       Date:  2004-11       Impact factor: 3.490

5.  Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp.

Authors:  L B Duffy; D Crabb; K Searcey; M C Kempf
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

6.  Formylation is not essential for initiation of protein synthesis in all eubacteria.

Authors:  D T Newton; C Creuzenet; D Mangroo
Journal:  J Biol Chem       Date:  1999-08-06       Impact factor: 5.157

7.  A phylogenetic analysis of the mycoplasmas: basis for their classification.

Authors:  W G Weisburg; J G Tully; D L Rose; J P Petzel; H Oyaizu; D Yang; L Mandelco; J Sechrest; T G Lawrence; J Van Etten
Journal:  J Bacteriol       Date:  1989-12       Impact factor: 3.490

Review 8.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.

Authors:  Ronald N Jones; Gary J Moet; Helio S Sader; Thomas R Fritsche
Journal:  J Antimicrob Chemother       Date:  2004-03-31       Impact factor: 5.790

10.  In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Xue Bing; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191
View more
  3 in total

1.  Activity of LBM415 compared to those of 11 other agents against Haemophilus species.

Authors:  Tatiana Bogdanovich; Kathy A Smith; Catherine Clark; Glenn A Pankuch; Gengrong Lin; Pamela McGhee; Bonifacio Dewasse; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 2.  Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.

Authors:  Tracy Swainston Harrison; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Drug forecast - the peptide deformylase inhibitors as antibacterial agents.

Authors:  David R P Guay
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.